Marinomed Biotech AG announces grant of Chinese Patent covering the proprietary Marinosolv technology to generate aqueous solutions from insoluble compounds

China grants patent protection for proprietary Marinosolv platform, a technology to enable significantly improved solubility of drugs in aqueous solutions, increasing bioavailability

Korneuburg, Austria, July 15, 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, is pleased to announce that the Chinese State Intellectual Property Office (SIPO) has granted the patent covering the Marinosolv platform and its solubilizer properties. Specifically, the patent protects Marinosolv as a method for generating aqueous solutions of therapeutically or cosmetically relevant organic compounds that are insoluble or only slightly soluble in water. The Marinosolv platform enables the solubilization of many hardly soluble compounds, which opens new possibilities for precisely treating a multitude of diseases.

"The Marinosolv patent in China is an important international reinforcement of the technology platform and supports our continued efforts in further establishing and advancing Marinosolv-based products. We consider both the Marinosolv-based products and the underlying technology central cornerstones for the company's future development," said Dr. Andreas Grassauer, Chief Executive Officer of Marinomed. "The Chinese market offers huge potential for the treatment of allergic diseases. This patent will help Marinomed to benefit from these opportunities."

"The data from Marinosolv formulated product candidates so far have demonstrated significant efficacy given the comparatively low dosage: this is true for Tacrosolv, a soluble Tacrolimus formulation in development to treat hay fever, as well as for our two corticosteroid formulations against allergic rhinitis, Budesolv and Flutisolv. The increased solubility enables a significantly faster onset of action, better bioavailability and more efficient delivery, making treatment more convenient for patients," said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. "We are confident that formulations based on the Marinosolv technology generally offer much quicker improvement of symptoms for patients suffering from allergic rhinitis, allergic conjunctivitis and a broad range of further conditions where faster relief leads to a significantly improved quality of life."

Marinosolv is a proprietary technology platform enabling aqueous formulations of otherwise poorly soluble compounds. The platform opens application areas for a wide range of therapeutics, unlocking new treatment opportunities. Tacrosolv eye drops have recently successfully completed a Phase II clinical trial in patients with allergic rhinoconjunctivitis. Two corticosteroid formulations against allergic rhinitis are also in advanced development, Budesolv and Flutisolv. Budesolv, a Marinosolv-based Budesonide formulation, has successfully completed a clinical phase III study. For the Fluticasone-based Flutisolv, Marinomed is currently preparing the next step in clinical development. Beyond this late-stage clinical pipeline, Marinosolv also gives rise to a research pipeline, including potential treatment approaches for autoimmune gastritis and other indications.

The solubility and bioavailability of an active pharmaceutical ingredient (API) are central challenges in all pharmaceutical drug development programs and can be a major hurdle for the success of drugs in clinical development. Marinomed developed the Marinosolv platform to specifically address this challenge. Preclinical and clinical studies have shown that Marinosolv-based formulations achieve a higher concentration in the target location or tissue compared to suspensions and other standard formulations, resulting in a better local bioavailability. Besides this, the Marinosolv platform can extend the patent life of approved drugs.

About Marinosolv^(R):
Marinosolv^(R) is an innovative technology platform that enables solubilization of many barely soluble compounds and in consequence, opens new possibilities in treating a multitude of diseases. While organic compounds could previously often only be delivered as a suspension, Marinosolv^(R) provides aqueous formulations without preservatives with a faster onset of action and increased local bioavailability. In addition, they can be used without prior shaking, thus improving usability and enabling reliable dosing in sensitive tissues such as eyes or nose. Overall, the use of the Marinosolv^(R) technology can facilitate efficient drug delivery with high local availability and low systemic off-target activity. Even off-patent active ingredients can be patented as part of new formulations developed using Marinosolv^(R), while keeping production processes cost-efficient. For more information on Marinosolv^(R), please visit , and for a list of scientific publications on Marinosolv^(R), .

About Marinomed Biotech AG:
Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics listed on the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on two patent-protected technology platforms. The Marinosolv^(R) technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose^(R) platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose^(R) is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Marinomed^(R), Marinosolv^(R) and Carragelose^(R) are registered trademarks of Marinomed AG. These trademarks may be owned or licensed in select locations only. Further information is available at .

For further inquiries contact:

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.